Exactech Grows AI Expertise with Exclusive Machine-Learning Based Software Licensing Agreement and Team of Data Scientists
Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced it has exclusively licensed new software from Advata that will extend the capabilities of its innovative machine learning (ML)-based clinical decision support tool, Predict+. This newly licensed software is a powerful addition to the company’s Active Intelligence platform that will further facilitate Predict+ integration with the Equinoxe Planning App and will also encourage integration with other software and databases.
Recommended AI: The Future of AI Is Here. Now Let’s Make It Ethical
“Exactech is leading the orthopaedic industry in ML research and software applications.1-7 I am proud of Exactech’s vision to utilize enabling technologies with the goal of improving clinical outcomes and for making this investment to expand our in-house artificial intelligence capabilities”
Developed in partnership with Advata in 2019 and released in November 2020, Predict+ is a data-driven, clinical decision support tool and the first software of its kind to use ML to generate personalized risk-benefit analyses to help predict patient outcomes after shoulder replacement surgery.1-7 This software was designed to better inform surgeons regarding the expected outcomes that can be achieved after shoulder arthroplasty, based on the clinical experience documented within the world’s largest single-shoulder prosthesis outcomes database of more than 15,000 patients. These personalized predictions quantify the risk and benefit that an individual patient may experience after anatomic and reverse shoulder replacement.
“Advata is proud of the productive research and development collaboration with Exactech over the past several years. With the help of Advata’s exclusively licensed software for orthopaedic applications, Exactech now hosts Predict+ and can steward the continued development of this innovative ML-based product. This licensed software will encourage new innovations and improvements in usability of Predict+ and other future applications,” said Sudarshan Chitre, Advata’s Chief Technology Officer.
Additionally, Exactech is pleased to announce that it has hired an established team of machine learning researchers and engineers that will further accelerate Exactech’s ML research and development capabilities and improve its ability to produce additional innovative artificial intelligence-based software for various orthopaedic applications.
Recommended AI: AiThority Interview with Jessica Kipper, Senior Director, Software Product Management at Schneider Electric
“Exactech is leading the orthopaedic industry in ML research and software applications.1-7 I am proud of Exactech’s vision to utilize enabling technologies with the goal of improving clinical outcomes and for making this investment to expand our in-house artificial intelligence capabilities,” said Chris Roche, Exactech’s Senior Vice President of Extremities. “This investment in new software and the hiring of this amazing machine learning team will serve as a catalyst for even more powerful and predictive artificial intelligence research and development applications for the Equinoxe shoulder, and also for other Exactech hip, knee and ankle products.”
“My team and I share Exactech’s vision that machine learning has the potential to transform healthcare decision making,” said Vikas Kumar, Exactech’s new Vice President of Machine Learning. “When paired with high quality healthcare data, novel ML applications will provide orthopaedic surgeons with valuable new data to help them make more informed, evidence-based decisions through which we aim to optimize clinical outcomes after arthroplasty. My team and I are proud of what we have developed with Exactech since 2019, and we are excited about what we will develop and deploy in the years to come at Exactech.”
Recommended AI: AiThority Interview with Pete Wurman, Director at Sony AI
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.